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Chlamydia pneumoniae, an obligate intracellular
human pathogen, causes a number of respiratory
diseases. We explored the role of the conserved
OmcB protein in C. pneumoniae infections, using
yeast display technology. (i) Yeast cells presenting
OmcB were found to adhere to human epithelial cells.
(ii) Pre-incubation of OmcB yeast cells with heparin,
but not other glycosaminoglycans (GAGs), abrogated
adhesion. (iii) Pre-treatment of the target cells with
heparinase inhibited adherence, and GAG-deﬁcient
CHO cell lines failed to bind OmcB yeast. (iv) A
heparin-binding motif present near the N-terminus of
OmcB is required for host cell binding. (v) Pre-
treatment of chlamydial elementary bodies (EBs) with
anti-OmcB antibody or pre-incubation of target cells
with recombinant OmcB protein reduced infectivity
upon challenge with C. pneumoniae. (vi) Adhesion of
ﬂuorescently labelled EBs to epithelial or endothelial
cells was abrogated by prior addition of heparin or
OmcB protein. Thus, C. pneumoniae O m c Bi sa n
adhesin that binds heparan sulphate-like GAGs.
OmcB from Chlamydia trachomatis serovar L1 also
adheres to human cells in a heparin-dependent way,
unlike its counterpart from serovar E. We show that a
single position in the OmcB sequence determines
heparin dependence/independence, and variations
there may reﬂect differences between the two sero-
vars in cell tropism and disease pattern.
Introduction
Chlamydia cause widespread infections in humans, other
mammals and birds. Chlamydia trachomatis, a pathogen
of mucosal surfaces, is one of the leading causes of
sexually transmitted disease and the most common cause
of preventable blindness worldwide (Schachter, 1999;
Byrne and Ojcius, 2004). Chlamydia psittaci infects birds
and occasionally causes psittacosis in humans, while
C. pneumoniae was ﬁrst isolated as a respiratory
pathogen. Exposure to C. pneumoniae is very common
and the prevalence of infection increases with age
(Grayston, 2000). C. pneumoniae infections cause
approximately 10% of community-acquired pneumonia
and 5% of bronchitis and sinusitis cases (Grayston,
1992). In addition, C. pneumoniae infections have been
implicated in the aetiology of stroke, atherosclerosis,
Alzheimer’s disease and multiple sclerosis (Saikku, 2000;
Lindsberg and Grau, 2003; Mussa et al., 2006; Stratton
and Wheldon, 2006). Evidence for an association
between C. pneumoniae and atherogenesis stems from
the fact that these bacteria have been detected in athero-
sclerotic plaques and isolated in culture from coronary
arteries (Kuo et al., 1993; Maass et al., 1998). Further-
more, chlamydia are also associated with various chronic
diseases, ranging from reactive arthritis to asthma (Kuo
et al., 1995; Von Hertzen, 2002; Zeidler et al., 2004). It is
not clear whether persistence of an unresolved chlamy-
dial infection or repeated chlamydial infections are rel-
evant for these chronic diseases (Hogan et al., 2004).
Chlamydia are pathogenic, Gram-negative, obligate
intracellular eubacteria with a unique biphasic develop-
mental cycle involving two different cell forms (Moulder
et al., 1984; Abdelrahman and Belland, 2005). Infectious
but metabolically inert elementary bodies (EBs) adhere
to eukaryotic host cells, stimulating their own uptake.
Internalized EBs remain in an intracellular compartment
termed an inclusion, where they differentiate into meta-
bolically active but non-infectious reticulate bodies (RBs),
which divide by binary ﬁssion. After 9–11 generations the
RBs re-differentiate into EBs, which are then released
from the host cell to start a new round of infection
(reviewed in Abdelrahman and Belland, 2005).
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divided into several distinct stages. Bacterial adherence
to host cell surfaces is the ﬁrst step in the establishment of
an infection and is a prerequisite for all subsequent
events. At this early stage of infection the speciﬁcity of the
pathogen–host cell interaction is determined by bacterial
surface proteins (adhesins) and receptors on the host cell
surface. These speciﬁc interactions may also help deter-
mine the cell and tissue tropism of the bacteria (Finlay and
Falkow, 1989; Boyle and Finlay, 2003; Pizarro-Cerda and
Cossart, 2006). Glycosaminoglycan (GAG) structures on
the mammalian cell surface play an important role in inter-
actions with many microbial pathogens, and are recog-
nized by a number of viral, bacterial and protozoan
adhesins (Rostand and Esko, 1997; Wadstrom and
Ljungh, 1999; Menozzi et al., 2002). Chlamydia can infect
a variety of non-phagocytic animal cell types, indicating
that the bacterial adhesins recognize conserved cellular
receptors and/or that EB attachment is mediated by
a variety of different adhesin–receptor combinations
(reviewed in Hackstadt, 1999; Abdelrahman and Belland,
2005; Dautry-Varsat et al., 2005; Campbell and Kuo,
2006). Despite the essential role of the adhesion process,
we have only limited knowledge of the nature of the
chlamydial adhesins and their receptors (Dautry-Varsat
et al., 2005; Campbell and Kuo, 2006). A number of
studies have implied that GAGs are required for the initial
phase of the chlamydial EB attachment process (Zhang
and Stephens, 1992; Chen and Stephens, 1994; 1997;
Zaretzky et al., 1995; Chen et al., 1996; Davis and Wyrick,
1997; Gutierrez-Martin et al., 1997). Thus, the addition of
exogenous heparan sulphate, or the heparan sulphate
analogue heparin, inhibits infection by C. trachomatis,
C. psittaci and C. pneumoniae, although the degree of
inhibition observed is dependent on the chlamydial
species, biovar, isolate and human cell line used
(Chen and Stephens, 1997; Gutierrez-Martin et al., 1997;
Taraktchoglou et al., 2001; Wuppermann et al., 2001;
Yabushita et al., 2002; Beswick et al., 2003; Darville et al.,
2004; Yan et al., 2006). Speciﬁcally, comparative studies
of the two C. trachomatis biovars, the trachoma biovar
(serovars A through K) and the lymphogranuloma
venereum (LGV) biovar (serovars L1, L2 and L3), which
differ in their infection characteristics and invasiveness in
clinical disease, display different GAG dependencies
(reviewed in Campbell and Kuo, 2006). While heparan
sulphate blocks binding of the LGV biovar to both non-
polarized and polarized human epithelial cells, binding of
serovar B or E EBs is only partly inhibited or even unaf-
fected (Chen and Stephens, 1997; Davis and Wyrick,
1997; Taraktchoglou et al., 2001). This suggests that the
more invasive LGV biovars, which are primarily submu-
cosal pathogens, may use heparan sulphate as an
adhesin to colonize basolateral domains of the mucosal
epithelium, while serovar E may use other GAGs (Camp-
bell and Kuo, 2006). For C. trachomatis a trimolecular
mechanism has been proposed, in which GAG-like struc-
tures serve as a bridge between an adhesin on the EB
and a receptor on the host cell surface (Zhang
and Stephens, 1992; Rasmussen-Lathrop et al., 2000;
Stephens et al., 2006). For C. pneumoniae it has been
shown that binding of EBs to heparin sulphate-like GAGs
on the host cell surface is a prerequisite for subsequent
infection (Wuppermann et al., 2001). More recently it was
reported, for other C. pneumoniae strains and other
eukaryotic cell lines, that GAGs on the surfaces of both
target cells and EBs may play a role in invasion (Beswick
et al., 2003; Yan et al., 2006). The role of heparan
sulphate-like GAGs in infection by C. pneumoniae is
also supported by the fact that the induction of
pro-inﬂammatory cytokine gene expression by a
C. pneumoniae infection depends on adherence of the
bacteria to human lung epithelial cells and can be blocked
by addition of heparin (Yang et al., 2003).
Indeed, the GAG-binding outer membrane protein
OmcB from C. trachomatis L2 was identiﬁed by heparin
affinity chromatography, although its role in the chlamy-
dial adhesion process and its relevance for infection
remained unknown (Stephens et al., 2001). OmcB was
originally identiﬁed as a major component of the chlamy-
dial outer membrane complex, and is conserved among
all chlamydial species (Wagels et al., 1994; Hatch,
1999). OmcB has been variously localized to the peri-
plasm or the outer membrane of EBs (Watson et al.,
1994; Everett and Hatch, 1995; Ting et al., 1995; Mygind
et al., 1998; Stephens et al., 2001). However, during
chlamydial infections OmcB induces a strong antibody
response, suggesting that it is readily accessible to the
humoral immune response, which suggests a surface
localization for it (Wagels et al., 1994; Mygind et al.,
1998; Cunningham and Ward, 2003; Klein et al., 2003;
Portig et al., 2003).
The absence of a genetic system for chlamydia makes
the identiﬁcation and functional characterization of
chlamydial proteins involved in the adhesion process par-
ticularly difficult. To overcome these limitations we have
used a new test system for the functional characterization
of adhesion proteins. Display of heterologous proteins on
the surface of phages or microorganisms like Escherichia
coli, Gram-positive bacteria or yeast has proven to be
extremely useful in a number of experimental settings,
such as the development of a live vaccine, design of
whole-cell biocatalysts or screening of antibody libraries
(Georgiou et al., 1997; Kondo and Ueda, 2004; Jostock
and Dubel, 2005; Mullen et al., 2006). Yeast surface
display technology offers the additional advantages that
(i) all cloning steps are readily performed by homologous
recombination in yeast and (ii) the size of the protein to be
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Swers et al., 2004). In the yeast display system yeast
cells express a fusion protein comprising the a-agglutinin
protein Aga2 linked to the protein of interest; this is then
secreted and binds via disulphide bridges to the cell wall
protein Aga1 (Boder and Wittrup, 1997).
In order to study the function of the C. pneumoniae
OmcB protein we established a yeast adhesion system in
which the binding of live OmcB-presenting yeast cells to
human cells could be studied. Here we show that the
OmcB protein from C. pneumoniae mediates adhesion to
human epithelial HEp-2 cells. OmcB adhesion is depen-
dent on the N-terminal domain of the protein and a
heparin-binding motif present in this region. Infection inhi-
bition experiments using recombinant C. pneumoniae
OmcB protein or OmcB antibodies reveal that OmcB is
essential for infection, and speciﬁcally is involved in the
adhesion of the infectious EBs to the target cells. The
ability of OmcB proteins to bind to human cells seems to
be a general property of chlamydia, as OmcB from the
C. trachomatis serovars L1 and E (and from Chlamydia
caviae) adheres to HEp-2 cells. Intriguingly binding of the
OmcB protein from C. trachomatis serovar E to HEp-2
cells is completely independent of heparin, suggesting
differences in the mode of host cell invasion in vivo.
Our mutational analysis of the OmcB proteins from
C. trachomatis L1 and E indicates that binding can be
switched from heparin independence to heparin depen-
dence by changing a single amino acid.
Results
The yeast display system identiﬁes C. pneumoniae
OmcB as an adhesion protein
The adhesion of C. pneumoniae to host cells is the ﬁrst
and crucial step in bacterial pathogenesis. As this patho-
gen cannot be genetically manipulated, we used the het-
erologous yeast display system to study the adhesion
properties of chlamydial proteins. In this system, Saccha-
romyces cerevisiae cells express heterologous proteins
on their surfaces (Fig. 1A). The protein of interest is
expressed as a fusion protein with the yeast a-agglutinin
receptor subunit Aga2, which is anchored to the yeast cell
wall via its interaction with the resident Aga1 subunit
(Fig. 1A) (Boder and Wittrup, 1997). Expression of Aga2
and Aga2 fusion proteins occurs via the galactose-
inducible GAL1 promoter on a plasmid (Boder and
Wittrup, 1997). We expressed Aga2, Aga2 fused to the
adhesion domain [amino acid (aa) 790 to aa 986] of the
Yersinia pseudotuberculosis invasin (Dersch and Isberg,
1999), referred to here as Aga2–Inv, and Aga2–OmcB
(C. pneumoniae OmcB) in yeast. All three proteins were
expressed in similar amounts (Fig. 1B), andAga2–Inv and
Aga2–OmcB could be detected on the yeast cell surface
with anti-invasin and anti-OmcB antibodies respectively
(Fig. 1C).
To test whether the yeast display system was suitable
for the identiﬁcation of bacterial adhesins, we incubated
various numbers of yeast cells expressing the well-
deﬁned invasin adhesion domain (aa 790–986) with
1 ¥ 105 HEp-2 cells seeded on glass coverslips. In con-
trast to untransformed yeast cells or yeast cells express-
ing Aga2, yeast cells presenting the Aga2–Inv fusion
protein on the cell surface showed a high affinity for
HEp-2 cells (Fig. 1D). In particular, we found that the ratio
of Aga2–Inv yeast cells to HEp-2 cells correlated directly
with the number of yeast cells adhering to the human cells
(Fig. 1D). This was not observed for untransformed yeast
cells or Aga2-expressing yeast cells (Fig. 1D). Thus, the
yeast display system is indeed a suitable model with
which to study the adhesion properties of bacterial
proteins.
Microscopic inspection revealed that Aga2–Inv yeast
cells mainly bound laterally to HEp-2 cells and bud-
forming yeast cells showed uniform binding via the mother
cell and the bud (data not shown). Invasin-coated latex
beads not only adhere to human cells but are also taken
up by them (Dersch and Isberg, 1999). However, when
we performed our yeast adhesion experiments at 37°C
uptake of the invasin-coated yeast cells was not observed
(data not shown).
Next, we tested if the C. pneumoniae OmcB protein had
adhesive properties by analysing the ability of Aga2–
OmcB-expressing yeast cells to adhere to HEp-2 cells.
We found that Aga2–OmcB yeast cells were able to
adhere to HEp-2 cells just like Aga2–Inv yeast cells
(Fig. 1E and F). Proteolytic degradation of the surface-
expressed Aga2–OmcB fusion protein by proteinase K or
trypsin led to a complete loss of adhesion (Fig. 1G, data
not shown). Thus, OmcB mediates adhesion of yeast cells
to HEp-2 cells.
The C. pneumoniae OmcB binds to heparan
sulphate-like structures on host cells
Adhesion of, and subsequent infection by, C. pneumoniae
is dependent on GAGs such as heparan sulphate present
on the host cell (Davis and Wyrick, 1997; Wuppermann
et al., 2001; Beswick et al., 2003). To test if GAGs also
play a role in the adhesion of C. pneumoniae mediated
by OmcB, we pre-incubated Aga2- and Aga2–OmcB-
expressing yeast cells with various soluble GAG deriva-
tives prior to the adhesion assays. Pre-incubation with
heparin, a commonly used analogue for heparan sul-
phate, rendered Aga2–OmcB cells unable to adhere to
HEp-2 cells (Fig. 2A). Other GAGs, such as chondroitin-
6-sulphate (C-6-S), dermatan sulphate (DS) or
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binding of Aga2–OmcB yeast to HEp-2 cells (Fig. 2A).
Thus OmcB speciﬁcally binds heparin-like GAGs.
Further support for the idea that OmcB binds heparin-
like structures comes from our observation that enzymatic
removal of the heparan sulphate structures from the
surface of HEp-2 cells strongly inhibited binding of Aga2–
OmcB yeast cells, while adhesion of Aga2–Inv yeast cells
to HEp-2 cells was unaffected by treatment of the latter
with heparinase I (Fig. 2B). Our ﬁnding that OmcB present
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ported by the results of yeast adhesion assays using the
CHO mutant cell lines pgsA-745 and pgsD-677 as targets
(Fig. 2C). These cell lines are defective in GAG biosyn-
thesis (Esko et al., 1985). The pgsA-745 line is unable to
synthesize any GAGs, while pgsD-677 cannot synthesize
heparan sulphate but accumulates chondroitin sulphate.
Aga2–OmcB yeast cells were able to adhere to wild-type
CHO-K1 cells, but were unable to associate with pgsA-
645 or pgsD-677 cells (Fig. 2C). These results conﬁrm
that OmcB binds heparan sulphate-like GAGs on human
cells.
The N-terminal part of OmcB is required for adhesion
To identify the domain of the C. pneumoniae OmcB that
mediates binding to human cells we generated truncated
versions of the protein and tested them in the yeast
display system. Western blot analysis revealed that the
truncation mutants are produced in similar amounts to the
full-length protein (Fig. 3A). A C-terminal OmcB deletion
variant, Aga2–OmcB1-282, behaved like wild-type OmcB,
while the N-terminal deletion variant Aga2–OmcB275-556
showed no adhesive properties (Fig. 3A). Thus the
N-terminal part of OmcB harbours the binding domain
required for adhesion.
This portion of the protein has a large number of basic
amino acids, particularly in the stretch between amino
acids 41 and 79. Basic amino acids have been shown to
be important for the binding of proteins to GAGs (Cardin
and Weintraub, 1989; Hileman et al., 1998; Stephens
et al., 2001). We therefore created the OmcB deletion
variant OmcBD45-78, which lacks amino acids 45–78, and
tested this variant in our yeast adhesion assay. Yeast cells
expressing Aga2–OmcBD45-78 were unable to adhere to
HEp-2 cells (Fig. 3A), implying that the basic region plays
an important role in the adhesion process. A sequence
comparison of OmcB homologues from various chlamy-
dial species revealed that this region of the
C. pneumoniae OmcB protein harboured two putative
heparin-binding motifs (amino acids 53–58 and 59–64
respectively) with the consensus sequence XBBXBX
(X = hydropathic amino acid, B = basic amino acid)
(Hileman et al., 1998) (Fig. 3B). The ﬁrst motif is con-
served among OmcB proteins from all chlamydia, with the
exception of environmental Parachlamydia. To test
whether such a heparin-binding motif was required for
adhesion, we replaced several of the basic amino acids
found in heparin-binding motif I with alanines, and tested
the ability of the mutant protein to function in our yeast
adhesion assay. All mutations were generated in the
N-terminal variant OmcB1-100. Yeast cells expressing
Aga2–OmcB and Aga2–OmcB1-100 display comparable
levels of adhesion to HEp-2 cells, indicating that the
OmcB1-100 segment is mainly responsible for adhesion
(Fig. 3Aand B). Using site-directed mutagenesis, we gen-
erated OmcB1-100 variants with single-amino-acid changes
at positions 54 (lysine to alanine), 55 (lysine to alanine)
and 57 (arginine to alanine) respectively (Fig. 3B). Sub-
stitution of the lysine residues decreased adhesion by 5%
or 10% (OmcB1-100K54A and OmcB1-100K55A respectively)
compared with wild-type OmcB1-100. Replacement of the
arginine residue reduced adhesion by 35% (Fig. 3B).
When all three mutations were combined in the variant
OmcB1-100K54K55R57A adhesion was completely abolished
(Fig. 3B). Thus heparin-binding motif I is required for
adhesion, and the basic amino acids present in this
sequence all contribute to this function, although to
varying degrees.
In an effort to conﬁrm the results obtained with the yeast
display system, we employed the well-established latex
bead assay (Dersch and Isberg, 1999). To this end, full-
length OmcB and OmcBD45-78 were expressed in and puri-
ﬁed from E. coli (Fig. 4A). Similar amounts of the puriﬁed
OmcB variants were coupled to latex beads (Fig. 4B),
which were then tested for the ability to adhere to HEp-2
Fig. 1. Yeast cells expressing Aga2–Inv or Aga2–OmcB adhere to human cells.
A. Schematic representation of the yeast display system. The protein of interest is presented on the yeast cell surface as a consequence of its
fusion to Aga2p.
B. Western analysis of Aga2 (lane 1), Aga2–Inv (lane 2) and Aga2–OmcB (lane 3). Left: Protein extracts from strains expressing Aga2,
Aga2–Inv or Aga2–OmcB were digested with a-mannosidase to remove Aga2 O-glycosylation, resolved by SDS-PAGE and probed with an
anti-His antibody. Right: Coomassie-stained SDS-PAGE of the protein extracts shown in the left panel. The positions of the size markers (250,
98, 50 and 22 kDa) are indicated.
C. Detection of Aga2 fusion proteins on the yeast cell surface. Yeast cells expressing Aga2, Aga2–Inv or Aga2–OmcB were ﬁxed and stained
with anti-invasin or anti-OmcB antibodies for visualization of Aga2–Inv and Aga2–OmcB proteins respectively. Bar 1 mm.
D–G. Adhesion of yeast cells to HEp-2 cells. (D) Varying numbers of untransformed yeast cells or yeast cells expressing Aga2 or Aga2–Inv
from a plasmid were incubated with 1 ¥ 10
5 HEp-2 cells, and the number of yeast cells associated with HEp-2 cells was determined by
microscopy. (n = 1000 HEp-2 cells, No. experiments = 4, P < 0.0001). (E) Schematic representation of the numbers of yeast control cells or
yeast cells expressing Aga2, Aga2–Inv and Aga2–OmcB adhering
to 1000 HEp-2 cells. (n = 1000 HEp-2 cells,
No. experiments = 4, P < 0.0001). (F) Photomicrographs of HEp-2 cells after incubation with yeast cells expressing the indicated proteins. Bar
10 mm. The cells indicated by the white box are shown enlarged in the rightmost panel. Bar 5 mm. (G) Adhesion of Aga2 or
Aga2–OmcB-expressing yeast cells to HEp-2 cells. Yeast cells (1 ¥ 10
6) were treated with PBS or proteinase K (4 mg ml
-1) for 1 h at 37°C,
washed three times and then added to HEp-2 cells (n = 1000 HEp-2 cells, No. experiments = 4, P < 0.0001).
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A. Left: Aga2- or Aga2–OmcB-expressing yeast cells were incubated with 500 mgm l
-1 of the soluble GAGs heparin, chondroitin-6-sulphate
(C-6-S), dermatan sulphate (DS) or chondroitin-4-sulphate (C-6-S) prior to the adhesion assay and the numbers of yeast cells adhering to
human cells were determined by microscopy. Yeast cells treated with PBS served as controls (n = 1000 HEp-2 cells, No. experiments = 4,
P < 0.0001). Right: Photomicrographs of GAG-treated Aga2–OmcB-expressing yeast cells adhering to human cells. Bar 10 mm.
B. Effects of treatment with heparinase on the ability of HEp-2 cells to bind Aga2-, Aga2–Inv- and Aga2–OmcB-expressing yeast cells. HEp-2
cells were incubated with PBS or 50 U heparinase I prior to the adhesion experiment. The photomicrographs show adhesion of
Aga2–OmcB-expressing yeast cells to HEp-2 cells.
C. Efficiency of association of Aga2- or Aga2–OmcB-expressing yeast cells with wild-type (CHO-K1) or GAG-deﬁcient (pgsA-745 and
pgsD-677) cell lines is plotted diagrammatically and illustrated in the photomicrographs. Bar 10 mm( n = 1000 cells, No. experiments = 4,
P < 0.01).
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were able to adhere to HEp-2 cells, while beads bearing
OmcBD45-78 could not (Fig. 4C). In addition, increasing the
amounts of OmcB attached to beads enhanced their ability
to associate with HEp-2 cells (Fig. S1).As expected adhe-
sion of beads coated with the wild-type OmcB was sensi-
tive to heparin (data not shown).
The C. pneumoniae OmcB is localized to the surfaces
of EBs and RBs in infected HEp-2 cells
In order to act as an adhesin, OmcB must be exposed on
the surface of the bacterial cell. To investigate the local-
ization of OmcB, indirect immunoﬂuorescence micro-
scopy was performed on HEp-2 cells infected with
Fig. 3. OmcB protein variants and adhesion.
A. Top: Schematic representations of the
wild-type OmcB protein from C. pneumoniae,
and the deletion derivatives used here, with
basic amino acids (black bars), signal peptide
sequence (black box) and heparin-binding
motifs (grey box) indicated. Bottom left:
Western blot analysis of protein extracts
from strains expressing Aga2–OmcB1-282,
Aga2–OmcB275-556 and Aga2–OmcBD45-78. After
digestion with a-mannosidase, cell extracts
were resolved by SDS-PAGE and probed
with an anti-His antibody. Bottom right:
Adhesion of yeast cells expressing Aga2,
Aga2–OmcB1-282, Aga2–OmcB275-556 or
Aga2–OmcBD45-78 to HEp-2 cells. (n = 1000
HEp-2 cells, No. experiments = 4,
P < 0.0001).
B. Schematic representation of the amino acid
changes generated in the OmcB variant
Aga2–OmcB1-100. The heparin-binding motifs I
and II are indicated. These variants show
reduced adherence to HEp-2 cells (bottom
diagram) (n = 1000 HEp-2 cells, No.
experiments = 4, P < 0.0001).
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cells an antibody directed against the intrachlamydial
DnaK protein, as well as antibodies directed against the
extrachlamydial OmpA and OmcB proteins, reacted with
the bacteria in the inclusion (Fig. 5A). In formaldehyde-
ﬁxed cells, cross-linking of outer membrane proteins
renders intrachlamydial proteins inaccessible to the
antibody. Indeed the anti-DnaK antibody did not react with
formaldehyde-treated bacteria, but both anti-OmpA and
anti-OmcB antibodies did, indicating that they are present
on the bacterial cell surface (Fig. 5A). Similar experiments
on unﬁxed C. pneumoniae EBs conﬁrmed that both OmcB
and OmpA were surface-localized, whereas the DnaK
epitopes were not accessible to antibodies (Fig. 5B).
The OmcB protein mediates attachment and
subsequent infection of C. pneumoniae
Our data strongly indicate that the C. pneumoniae OmcB
protein is required for adhesion of the bacteria to HEp-2
cells in a GAG-dependent manner. This implies that
OmcB plays a part in the infection process. We therefore
tested whether prior addition of recombinant OmcB
protein to HEp-2 cells interfered with infection by
C. pneumoniae. Incubation of HEp-2 cells with various
amounts of recombinant OmcB (20–200 mgm l -1) strongly
inhibited subsequent infection by C. pneumoniae in a
dose-dependent manner (Fig. 6A). In contrast, prior incu-
bation of HEp-2 cells with the OmcBD45-78 variant had no
inﬂuence on infection (Fig. 6A). Next, we blocked OmcB
function by incubating puriﬁed chlamydial EBs with an
anti-OmcB antibody. Incubation of chlamydial EBs with
pre-immune serum did not decrease the incidence of
Fig. 4. Adhesion of OmcB-coated latex beads to human cells.
A. Affinity-puriﬁed, recombinant wild-type OmcB and OmcBD45-78
proteins (black arrows) were resolved by SDS-PAGE and stained
with Coomassie. Bands of higher molecular weight represent
contaminants, and bands of lower molecular weight are
degradation products. Positions of size markers (98, 64 and
50 kDa) are indicated.
B. Equal amounts of beads coated with OmcB or OmcBD45-78
protein (black arrows) were separated by SDS-PAGE and probed
with an anti-His antibody.
C. Adhesion of coated latex beads to HEp-2 cells. Latex beads
(1 ¥ 10
6) coated with 100 mg of BSA, OmcB or OmcBD45-78 were
incubated with 1 ¥ 10
5 HEp-2 cells and the numbers of beads
associated with HEp-2 cells were determined by microscopy.
(n = 1000 HEp-2 cells, No. experiments = 4, P < 0.0001).
Fig. 5. Localization of C. pneumoniae OmcB.
A. Photomicrographs of HEp-2 cells infected with C. pneumoniae at
moi 1 in the presence of 1.2 mgm l
-1 cycloheximide for 48 h. Cells
were ﬁxed with methanol to visualize intra- and extrachlamydial
antigens by staining with anti-DnaK, anti-OmpA and anti-OmcB
antibodies. Fixation with formaldehyde and permeabilization with
0.5% Triton X-100 was used to visualize extrachlamydial antigens
(Birkelund et al., 1990). Bar 10 mm.
B. Left panel: Photomicrograph of puriﬁed, non-ﬁxed
C. pneumoniae EBs stained with CFSE. Right panels: Equal
amounts of puriﬁed, non-ﬁxed C. pneumoniae EBs were used for
microimmunoﬂuorescence (MIF) analysis. Chlamydial antigens
were detected using anti-DnaK, anti-OmpA and anti-OmcB
antibodies. Bar 1 mm.
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body reduced infectivity by 60% (Fig. 6B).
To demonstrate directly that OmcB is an adhesin that is
essential for the attachment of C. pneumoniae to its target
cells, ELISA-based attachment assays and ﬂow cytomet-
ric analyses were employed. In the ELISA assay we mea-
sured the binding of puriﬁed chlamydial EBs to epithelial
HEp-2 cells (Fig. 6C). As expected, heparin-treated con-
trols showed signiﬁcantly less C. pneumoniae binding, in
agreement with the previously described effect of heparin
(Wuppermann et al., 2001). Presence of recombinant
OmcB protein led to a signiﬁcant decrease in EB attach-
ment to HEp-2 cells, whereas addition of OmcBD45-78
protein had no inhibitory effect (Fig. 6C). This result was
conﬁrmed by the cytometric analysis of binding of CFSE-
labelled EBs to epithelial and endothelial cells. The pres-
ence of recombinant OmcB protein led to a 70% and a
91% decrease in EB attachment to HEp-2 and HUVE
cells, respectively, whereas addition of OmcBD45-78 protein
had no inhibitory effect (Fig. 6D). We therefore concluded
that the recombinant OmcB protein occupies the GAG
binding site on epithelial and endothelial host cells, thus
inhibiting adhesion of EBs and subsequent infection.
Variations in the amino acid sequence of OmcB
correlate with GAG-dependent adhesion
Glycosaminoglycan-dependent infection has been
observed with various chlamydial species, such as
C. pneumoniae, C. caviae and C. trachomatis serovars
LGV (L1, L2), whereas infection with the C. trachomatis
serovars B and E appears to be rather independent of
GAG (Chen and Stephens, 1994; 1997; Gutierrez-Martin
et al., 1997; Taraktchoglou et al., 2001; Wuppermann
et al., 2001; Beswick et al., 2003).
We thus asked if the differences in GAG dependence of
infection were caused by sequence alterations found in
the various OmcB proteins. OmcB from C. caviae GPIC,
which shares 82% sequence identity with C. pneumoniae
OmcB, showed adhesion properties similar to those
of the C. pneumoniae protein (Fig. 7). The amino acid
sequences of C. pneumoniae and C. trachomatis sero-
vars LGV and E OmcB are 70% identical and all contain
the ﬁrst heparin-binding motif found in C. pneumoniae
OmcB (Fig. S2). The OmcB proteins from the two
C. trachomatis serovars L1 and E are very similar
(98% identity), differing in only 11 of 547 positions. One
of the differences is found in the vicinity of the con-
served heparin-binding motif, at residue 66 (proline in
C. trachomatis serovar L1 and leucine in C. trachomatis
serovar E). Interestingly, the GOR IV secondary structure
prediction program indicated that the different amino
acids found at position 66 might result in a change from a
helical structure (OmcB C. trachomatis serovar E) to a
coiled-coil structure (OmcB C. trachomatis serovar L1).
We thus decided to test the effect of changing the proline
at position 66 of C. trachomatis serovar L1 OmcB to
leucine. Analysis of the corresponding OmcB-L1 variant,
Fig. 6. Inhibition of infection by C. pneumoniae.
A and B. C. pneumoniae infection is inhibited by addition of
recombinant OmcB protein or an OmcB-speciﬁc antibody. (A)
HEp-2 cells (1 ¥ 10
6) were incubated with PBS, 200 mg of BSA, or
20 mgo r2 0 0mg of recombinant OmcB or OmcBD45-78 protein prior
to challenge with puriﬁed C. pneumoniae EBs. Cells were ﬁxed at
48 h post infection and the numbers of inclusions determined by
microscopy. The number of inclusions found in the PBS control was
set to 100%. (n = 20 microscopic ﬁelds, No. experiments = 4,
P < 0.0001). (B) Puriﬁed C. pneumoniae EBs were incubated with
PBS, pre-immune serum or anti-OmcB antibody before being
exposed to HEp-2 cells. The numbers of inclusions formed was
determined by microscopy 48 h post infection. (n = 20 microscopic
ﬁelds, No. experiments = 4, P < 0.0001).
C. Binding of puriﬁed C. pneumoniae EBs to HEp-2 cells was
detected by a colorimetric assay using a chlamydia-speciﬁc primary
antibody and a HRP-coupled secondary antibody. Attachment of
C. pneumoniae EBs in the presence of PBS or 200 mgo fB S A
served as controls, and these data were compared with samples to
which heparin (500 mgm l
-1) or recombinant OmcB or OmcBD45-78
protein (200 mg) had been added. (n = 2 wells, No. experiments = 6,
P < 0.01).
D. Adhesion of viable, CFSE-stained C. pneumoniae EBs to HEp-2
or human umbilical vein endothelial cells (HUVEC) was detected by
ﬂow cytometric analysis. The same amounts of protein and heparin
as in (C) were used in this experiment.
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that adhesion was no longer dependent on heparin
(Fig. 7). In the converse experiment we changed the
leucine at position 66 of C. trachomatis E OmcB to
proline. The subsequent analysis revealed that the
OmcB-E L66P variant behaved like the OmcB-L1 protein:
addition of heparin led to a 60% decrease in attachment of
yeast cells displaying this variant to HEp-2 cells. Thus, our
ﬁndings strongly imply that heparin dependence of infec-
tion can be conferred or reversed by a single-amino-acid
alteration in OmcB.
Discussion
Attachment of a pathogen to its host cell is the crucial ﬁrst
step in the infection process. Pathogenic microorganisms
express speciﬁc cell surface adhesins which interact with
eukaryotic cell surface molecules in order to enable sub-
sequent infection. It has been well documented that GAG
molecules play a role in the initial phase of the infection
process by chlamydia (Campbell and Kuo, 2006). We
have reported previously that one of the earliest steps in
C. pneumoniae infection is the adhesion of infectious EBs
to heparan sulphate-like GAGs on the target cell surface
(Wuppermann et al., 2001). The ﬁndings presented here
imply that the C. pneumoniae OmcB protein is the bacte-
rial adhesin that mediates binding to heparan sulphate-
like GAGs on human epithelial and endothelial cells, and
is important for the establishment of the chlamydial
infection. Interestingly, the OmcB proteins from C. tracho-
matis L1 and E, as well as from C. Caviae, all share
adhesive properties, although C. trachomatis L1 and E
differ in their dependency on GAGs.
The yeast display system allows identiﬁcation and
characterization of bacterial adhesin–receptor
interactions
In this study we demonstrate for the ﬁrst time the suitability
oftheyeastdisplaysystemfortheidentiﬁcationofbacterial
adhesins and the dissection of their interactions with host
cell receptors. The well-characterized invasin protein (Inv)
from Y. pseudotuberculosis, when presented on the yeast
cell surface, mediated adhesion to epithelial HEp-2 cells in
adose-dependentmanner.Theobservedlateralbindingof
Inv yeast cells to HEp-2 cells is reminiscent of the zipper-
like interaction mechanism of invasin-expressing Yersinia
cells with human cells, which is thought to maximize
adhesin–receptor interactions (Isberg et al., 1987; Dersch
and Isberg, 1999). Both invasin-expressing bacteria and
latexbeadscoatedwithinvasinaretakenupbyHEp-2cells
in a concentration-dependent manner (Dersch and Isberg,
1999). We did not observe uptake of Inv-expressing yeast
cells by HEp-2 cells when the adhesion experiment was
performedat37°C(datanotshown),suggestingeitherthat
the affinity of Inv yeast cells for HEp-2 cells might be
insufficient to promote uptake or that the larger size of the
yeast cells impairs this process.
Chlamydia most likely uses multiple adhesins on the EB
surface for interaction with the host cell (Campbell and
Kuo, 2006). We therefore tested other C. pneumoniae cell
surface proteins and found signiﬁcant adhesion of GroEL-
1-presenting yeast cells to HEp-2 cells (data not shown)
(Bavoil et al., 1990; Raulston et al., 1998) (F. Wupper-
mann, K. Mölleken, C.A. Jantos and J.H. Hegemann,
unpublished). In contrast, we observed no adhesion of
OmpA-presenting yeast cells to human cells (data not
shown). This may indicate that the C. pneumoniae OmpA
is functionally distinct from the OmpA expressed by the
C. trachomatis mouse pneumonitis serovar, which has
been shown to bind cellular heparan sulphate when incu-
bated as recombinant protein with human cells (Su et al.,
1996).
OmcB is located on the surface of EBs and RBs
In order to act as a cytoadhesin the OmcB protein must be
exposed on the cell surface. In our experiments viable
C. pneumoniae EBs could be stained with the polyclonal
anti-OmcB antibody, as was the replicating chlamydial
population within the inclusion during the entire infection
(Fig. 5A shows infected cells 48 h post infection), indicat-
Fig. 7. Assay of the GAG dependency of binding by C. caviae
OmcB and C. trachomatis OmcB variants. Schematic
representation of the adhesion of various yeast transformants to
HEp-2 cells. Yeast cells expressing Aga2, Aga2–OmcB-C.pn.,
Aga2–OmcB-C.ca. GPIC, Aga2–OmcB-C.tr. L1, Aga2–OmcB-C.tr.
E, Aga2–OmcB-C.tr.L 1P 66L or Aga2–OmcB-C.tr.EL 66P were
pre-incubated with 500 mgm l
-1 soluble heparin prior to the
adhesion assay. (n = 1000 HEp-2 cells, No. experiments = 4,
P < 0.0001). w/o, without; C.pn., C. pneumoniae; C.ca., C. caviae;
C.tr., C. trachomatis.
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EBs and RBs during the entire developmental cycle.
Recently other groups have also localized the
C. pneumoniae OmcB on the bacterial cell surface by
immune ﬂuorescence microscopy or FACS analysis using
polyclonal antibodies raised against the recombinant
protein (Montigiani et al., 2002; Vandahl et al., 2002).
However, there have been conﬂicting reports concerning
the localization of OmcB in C. trachomatis L2 and in
C. psittaci (Everett and Hatch, 1995; Ting et al., 1995;
Mygind et al., 1998; Stephens et al., 2001). Interestingly,
in those cases where a surface localization was found, the
authors described the speciﬁc accessibility of the OmcB
N-terminus on the EB cell surface (Ting et al., 1995;
Stephens et al., 2001). The surface accessibility of the
C. trachomatis OmcB N-terminus has also been predicted
based on the hydrophilicity proﬁle of the protein (Mygind
et al., 1998). These data are in accordance with our
ﬁnding that the OmcB adhesin function is located within
the ﬁrst 100 N-terminal amino acids.
The N-terminal region of OmcB is essential for host cell
adhesion and infection
The C. pneumoniae OmcB protein is very basic: 60 of its
556 amino acids (11%) are arginine or lysine residues.
However, the N-terminal region includes a particularly
basic domain (aa 41 to aa 79) with 26% basic residues
(10 aa/38 aa) and our deletion analysis revealed that the
heparan sulphate binding region was localized to this
basic domain. Furthermore, yeast cells presenting just the
N-terminal 100 amino acids (OmcB1-100) including the
basic domain exhibited the same adhesion properties as
the full-length OmcB protein, indicating that the N-terminal
portion is responsible for the entire adhesive activity of
OmcB. A detailed amino acid sequence analysis of the
basic domain revealed that the OmcB protein carries
a sequence motif which perfectly ﬁts the consensus
sequence XBBXBX identiﬁed previously as one of three
major binding motifs found in a variety of heparin-binding
proteins, including OmcB (Cardin and Weintraub, 1989;
Hileman et al., 1998; Stephens et al., 2001; Capila and
Linhardt, 2002). Interestingly, only in the C. pneumoniae
OmcB protein is this motif duplicated (Fig. 3B). Our muta-
tional analysis of the N-terminal motif (motif I) within the
OmcB protein revealed that changing all three basic resi-
dues to alanine completely abolished the adhesion of
OmcB yeast cells to HEp-2 cells, proving the relevance of
the motif for binding of heparan sulphate-like GAGs. It
remains to be seen whether motif II present in the
C. pneumoniae OmcB also contributes to GAG and
HEp-2 cell binding. It is possible that the duplication of the
heparin-binding motif confers unique properties on the
C. pneumoniae OmcB protein.
The OmcB proteins from C. trachomatis serovars L1
and E differ in the heparin dependence of their
adhesion behaviour
The OmcB protein is highly conserved among chlamydial
species (70–84% overall identity). Interestingly, the
highest sequence identity of 90–100% is limited to the
C-terminal part of the proteins (aa 96 to aa 556), while
the basic domain carrying the heparin-binding motif (aa
41 to aa 79) exhibits high sequence diversity, with identity
scores of 18–29% only (Mygind et al., 1998). Neverthe-
less, our analysis revealed that the OmcB proteins from
C. trachomatis L1 and E and from C. caviae all adhere to
epithelial human cells with similar affinities. Likewise, it
has been shown recently that E. coli cells expressing
OmcB from C. trachomatis L1 adhered to HeLa and
Hec-1B cells, and that recombinant OmcB protein, as well
as an anti-OmcB antibody, reduced the incidence of
C. trachomatis infection (Fadel and Eley, 2007).
We assume that host cell binding by these various
OmcB proteins always occurs via the N-terminal basic
domain carrying the heparin-binding motif. Because the
OmcB protein sequences are almost identical among the
various C. trachomatis serovars, they should have very
similar, if not identical, adhesion properties. Surprisingly
however, binding of OmcB from serovar E to human cells
was found not to be heparin dependent, while OmcB from
serovar L1 showed heparin dependency. Even a hundred-
fold increase in the amount of heparin, usually sufficient to
abrogate any OmcB binding to HEp-2 cells, failed to
reduce binding (data not shown). Sequence comparison
revealed that within the basic domains only three amino
acids differ between the two proteins. The mutational
analysis of position 66 in the OmcB proteins from
C. trachomatis L1 and E identiﬁed this position as being
crucial for binding of heparin-like GAG structures. We
found that the ability of C. trachomatis L1 OmcB to bind
heparin-like GAGs is completely abrogated by changing
the proline residue at position 66 to a lysine. Similarly,
adhesion of C. trachomatis E OmcB to HEp-2 cells, which
is normally completely independent of heparin-like GAGs,
can be strongly reduced by prior incubation of the
C. trachomatis EL 66P variant with heparin. These ﬁndings
support and extend the results of other studies which
have shown that C. trachomatis LGV infections can be
blocked by addition of heparin, while infection by serovar
E is less susceptible to interference by heparan sulphate
or other GAGs tested (Davis and Wyrick, 1997; Tarak-
tchoglou et al., 2001; Beswick et al., 2003). It has been
reported that attachment of EBs from C. trachomatis tra-
choma biovar strains B and C to HeLa 229 cells is also
only partially inhibited by exogenous heparin (Chen and
Stephens, 1997). The OmcB protein sequences of the
three trachoma serovars (serovars B, C, E) are identical in
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position 66 which is only found in serovar E. Thus the
C. trachomatis E L66P variant generated in this work
mimics the partial heparin resistance of serovars B and C.
The question remains why serovar E is the only trachoma
biovar identiﬁed thus far, which has evolved the particular
OmcB protein exhibiting adhesion to human epithelial
cells independent of heparin-like GAGs. The OmcB
protein sequences from other chlamydia differ signiﬁ-
cantly in the N-terminal basic domain from the trachoma
biovars, and it is therefore difficult to assess the impact of
this particular alteration at position 66 based on sequence
comparisons alone. Functional differences in heparin-
binding proteins between related species are also
observed in other organisms. The Mycobacterium tuber-
culosis adhesin heparin-binding haemagglutinin (HBHA)
binds via its C-terminal lysine-rich domain to heparin and
is relevant for binding to non-professional phagocytes.
The corresponding protein from Mycobacterium smegma-
tis shares 68% identity with its homologue and is associ-
ated with the cell wall, but exhibits low affinity for heparin,
probably due to a stretch of acidic residues preceding the
basic domain (Biet et al., 2007).
WhydotheOmcBproteinsfromC. trachomatisserovars
L1 and E exhibit different GAG dependencies? Serovar E
is thought to be a non-disseminating luminal pathogen,
entering and exiting the apical surfaces of columnar epi-
thelial cells lining the mucosa, and ascending via canaliculi
in the female genital tract. In contrast, serovar L1 is a
disseminating pathogen, exiting the basal surfaces of epi-
thelial cells and then spreading through the submucosa to
lymph nodes (Davis and Wyrick, 1997; Davis et al., 2002).
Despite these large differences in disease pattern, the
genomes of the different C. trachomatis serovars share
morethan99%identity(Deanet al.,2006),suggestingthat
small changes in individual genes may have profound
effects on the type of disease caused. Our ﬁndings are
compatible with the idea that the two C. trachomatis sero-
vars have evolved speciﬁc OmcB adhesins for different
niches. It has been demonstrated that heparan sulphate is
only localized to the basal membrane of genital columnar
epithelial cells of mouse tissue (Hayashiet al., 1987; Bern-
ﬁeld et al., 1999). Thus, C. trachomatis serovar E will only
be able to adhere to and invade the apical cell side by
exploiting a different, non-heparin-like structure, and this
might occur via a modiﬁed OmcB basic region. It has been
suggested that in the C. trachomatis strains the omcB
gene has diverged more rapidly than the ompA gene
(Millman et al., 2001). This might suggest that selection
pressure acted to diversify the N-terminal region of the
OmcB protein in order to optimize infection of speciﬁc cell
types. In contrast, the rest of the OmcB protein, which is
probably responsible for the rigid cell wall structure of the
EBs and for stabilization of the RB outer membrane during
the replicative phase, might face strong stabilizing selec-
tion pressure and thus undergoes little change.
The role of OmcB in chlamydial infection
Glycosaminoglycans have been implicated in cell attach-
ment and invasion by chlamydia species. Here we show
that OmcB from C. pneumoniae binds to heparin-like
GAG structures on human cells and probably is neces-
sary for chlamydial infections. However, the precise
chemical nature of the heparin-like structure recognized
by OmcB remains to be analysed. Originally we had
shown that C. pneumoniae strain GiD adheres to heparin-
like GAGs on the HEp-2 cell surface (Wuppermann et al.,
2001). New data indicate that other C. pneumoniae
strains and epithelial cell lines as well as endothelial cells
exhibit differences in GAG dependency, and evidence for
a role of GAGs located on the host cell surface and on the
surface of the infectious EB has been presented (Beswick
et al., 2003; Yan et al., 2006). Moreover, the infectivity of
C. pneumoniae strains could also be inhibited by chon-
droitin sulphate, although heparin treatment was more
effective. Taken together, these data suggest that the
GAG-binding proteins on the cell surface of different
C. pneumoniae strains might be variable (Beswick et al.,
2003; Yan et al., 2006). Alternatively, other EB surface
proteins may modulate the OmcB speciﬁcity for certain
GAGs or additional unknown GAG-binding proteins may
be present on the EB surface.
We propose that the attachment of C. pneumoniae to
human cells via OmcB–GAG interactions is only the ﬁrst
step towards successful internalization. Blocking this
initial interaction between the EB and the target cell by the
addition of excess amounts of soluble heparan sulphate
(Wuppermann et al., 2001) or recombinant OmcB or
OmcB antibody (this work) always results in a residual
infectivity of about 10%. This points to the presence of
additional, as yet unidentiﬁed adhesin–receptor interac-
tions which, in combination with the OmcB–GAG interac-
tion, might account in part for tissue tropism and the
spread of the pathogen.
The simplest infection model would postulate that
OmcB molecules present on the surface of C. pneu-
moniae EBs bind GAG structures located on the host cell
surface in order to initiate attachment. However, at
present it cannot be excluded that this bimolecular inter-
action is accompanied by a trimolecular interaction, in
which OmcB located on the EB surface binds speciﬁc
soluble (pathogen- or host cell-derived) GAGs or GAG-
like structures, which in turn are recognized by cellular
receptors. This latter mechanism has been proposed for
C. trachomatis by Stephens et al. who have shown that
the serovars L2 and D seem not to bind directly to
heparan sulphate on the host cell surface (Zhang and
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lar model has also been proposed for a number of other
bacteria, which may utilize speciﬁc GAGs as molecular
bridges to interact with a diverse array of mammalian
heparin-binding proteins (MHBPs) in order to optimize
pathogen–host interactions (Duensing et al., 1999).
Experimental procedures
Bacterial strains, yeast strains and cell culture
Escherichia coli strain XL-1 blue (Stratagene) was used for
protein expression and plasmid ampliﬁcation. C. pneumoniae
GiD, C. trachomatis serovars LGV (L1/440/Bu; ATCC No.
VR-902B) and E (DK-20; Institute of Ophthalmology, London)
were propagated in HEp-2 cells (ATCC No. CCL-23) as
described (Roblin et al., 1992; Jantos et al., 1997). Chlamy-
dial EBs were puriﬁed using a 30% gastrographin (Schering).
The CHO cell lines CHO-K1 (ATCC CCL-61), CHO pgsD-
677 (ATCC CRL-2244) and CHO pgsA-745 (ATCC CRL-
2242) were cultured in Ham’s F12-K nutrient mixture medium
(Invitrogen) (Esko et al., 1985; Lidholt et al., 1992). Human
umbilical vein endothelial cells (HUVEC), kindly provided by
Axel Gödecke, were cultivated through two passages in
endothelial cell medium.
The S. cerevisiae strain EBY100 (MATa ura3-52 trp1
leu2D1 his3D200 pep4:HIS3 prb1D1.6R can1 GAL) used for
adhesion experiments was grown in synthetic medium plus
2% raffinose (SR) or 2% galactose (SG) (Sherman, 1991)
(Invitrogen) (Boder and Wittrup, 1997).
DNA manipulations and plasmid construction
Plasmids containing chlamydial genes were generated by
homologous recombination in S. cerevisiae.
The full-length omcB coding sequence or omcB variants
were ampliﬁed by PCR from genomic C. pneumoniae GiD,
C. trachomatis serovar LGV L1/440/Bu, C. trachomatis
serovar E DK-20 or C. caviae GPIC DNA, and either cloned
directly into the EcoRI+NotI-digested pYD1 vector
(Invitrogen) or cloned into the BglII and EcoRI sites of the
pAC-2 vector after attachment of a 5′ sequence encoding
a His6-Tag. The adhesion domain sequence of
Y. pseudotuberculosis invasin (aa 790–986) was subcloned
from pRI284 (Dersch and Isberg, 1999) into EcoRI+NotI-
digested pYD1. Site-speciﬁc mutagenesis was performed
using the Quick Change II mutagenesis kit (Stratagene). All
constructs were sequenced prior to further use.
Protein expression and affinity puriﬁcation of
his6-tagged proteins
For expression of Aga2p or Aga2p fusion proteins in yeast
strain EBY100 cells were grown according to the users’
manual (Invitrogen) (Boder and Wittrup, 1997).
The expression and puriﬁcation of His6–OmcB fusion pro-
teins was performed under denaturing conditions following
the procedure recommended by Qiagen. Proteins were rena-
tured by dialysis against PBS, fractionated by SDS-PAGE
and detected by Western analysis with an anti-His antibody
(Qiagen).
Immunoblot analysis
SDS-PAGE and immunoblot analysis were performed as
described (Sambrook et al., 1989). For detection of Aga2p
fusion proteins, extracts from yeast cells were incubated
with 1 U of a-mannosidase for 2 h at 37°C to remove
O-glycosylation of Aga2 protein, resolved by SDS-PAGE and
visualized after incubation with anti-His (Qiagen) and
AP-conjugated anti-mouse antibodies (Promega).
Immunoﬂuorescence microscopy
HEp-2 cells on glass coverslips (12 mm diameter) were
washed once with PBS at 48 h post infection, ﬁxed with 3.7%
formaldehyde for 1 h and permeabilized with PBS containing
0.5% Triton X-100 or ﬁxed with 96% methanol for 10 min. The
monolayer was then washed three times with PBS (Birkelund
et al., 1990). For detection of chlamydial inclusions or
non-ﬁxed C. pneumoniae EBs, either anti-DnaK (Birkelund
et al., 1990), anti-OmpA (Dako) or anti-OmcB serum
(pre-absorbed, diluted 1:250) was used in combination with a
Cy3-conjugated anti-rabbit antibody (Sigma), or a mono-
clonal FITC-conjugated antibody raised against chlamydial
LPS was used (Bio-Rad).
Immunoﬂuorescence microscopy of yeast cells expressing
Aga2–Inv or Aga2–OmcB was performed on samples of
5 ¥ 10
6 cells grown for 24 h under inducing conditions. Cells
were washed twice with PBS and ﬁxed on glass slides coated
with poly-L-lysine. Slides were then incubated with PBS con-
taining 1% BSA, followed by incubation with anti-invasin
(Dersch and Isberg, 1999) or anti-OmcB and Cy3-conjugated
anti-rabbit antibodies (Invitrogen, Sigma). Cells were viewed
using a Zeiss Axioskop.
Adhesion assays
Yeast adhesion assay was performed with HEp-2 and CHO
cell lines cultivated on glass coverslips. Yeast cells (1 ¥ 10
6 in
1 ml of PBS) expressing a speciﬁc protein on the cell surface
were added to 1 ¥ 10
5 HEp-2 or CHO cells. Coverslips were
incubated for 1 h at 4°C with gentle shaking, washed three
times with 0.5 ml of PBS and ﬁxed with 3.7% formaldehyde.
The number of yeast cells attached to 1000 HEp-2 cells was
determined by microscopy. Each experiment was repeated
four times. We varied the ratio of yeast to HEp-2 cells, using
1:1, 5:1, 10:1 or 25:1, and found that a ratio of 10 yeast cells
per HEp-2 cell gave the most reproducible results. When
ratios greater than 25:1 were used it was difficult to determine
speciﬁc adhesion. For proteolytic digestion of surface-
exposed proteins yeast cells (1 ¥ 10
6) were incubated with
proteinase K (4 mg ml
-1) or trypsin (2.5 mg ml
-1) for 1 h at
37°C, blocked with 10 mg ml
-1 BSA for 1 h at room tempera-
ture, and washed three times with PBS before addition to the
HEp-2 cells. GAG-dependent adhesion was analysed by
treatment of HEp-2 or yeast cells with or without 50 U of
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500 mgm l
-1 soluble GAGs (heparin, C-6-S, dermatan sul-
phate or C-4-S; Sigma) to the yeast cells for 1 h at 4°C. Yeast
cells were washed three times with PBS prior to the adhesion
assays.
Adhesion assays with protein-coated latex beads were per-
formed as described (Dersch and Isberg, 1999). The coating
efficiency was analysed by immunoblotting. Latex beads
attached to samples of 1000 HEp-2 cells were counted under
the microscope in four independent experiments.
Infection inhibition assays
HEp-2 cells were cultivated on glass coverslips for 48 h to
give a conﬂuent monolayer, and incubated with 500 mlo f
medium containing recombinant protein (20–200 mgm l
-1 in
PBS) for 1 h at 37°C. Puriﬁed chlamydial EBs [multiplicity of
infection (moi) 100] were added to the protein suspension
and incubated for 1 h at 37°C without centrifugation. The high
moi was used to facilitate infection in order to avoid the
inﬂuence of the centrifugation procedure on the adhesion/
infection process. After removal of the supernatant, cells
were washed three times with PBS and incubated for 48 h in
medium containing 1.2 mgm l
-1 cycloheximide before ﬁxation
with methanol. For neutralization studies with anti-OmcB
serum, puriﬁed chlamydial particles (moi 100) were added to
500 ml of antibody suspension (pre-absorbed, diluted 1:250 in
PBS) and incubated for 1 h at 4°C. The mixture was then
added to untreated HEp-2 cells and incubated for 1 h at 37°C
without centrifugation. After three washes with PBS, cells
were incubated for 48 h in medium with cycloheximide before
ﬁxation with methanol. Inclusion formation was analysed by
immunoﬂuorescence microscopy as described above. The
number of inclusions in 80 microscopic ﬁelds (20 per cover-
slip) was determined, and the number found in PBS-treated
samples was set to 100%.
Bacterial adhesion assay
After pre-incubation of HEp-2 cells with 200 mgm l
-1 recombi-
nant protein or 500 mgm l
-1 heparin, puriﬁed chlamydial EBs
(moi 100) were added and incubated for 1 h. Cells were ﬁxed
with formaldehyde and adhering EBs were detected with a
C. pneumoniae-speciﬁc primary antibody followed by a
horseradish peroxidase (HRP)-coupled secondary antibody
(Dako).
Bacterial adhesion assay of CFSE-labelled
C. pneumoniae EBs by ﬂow cytometry
Puriﬁed C. pneumoniae EBs (2 ¥ 10
8) were labelled for 1 h at
37°C with 25 mmol of CFSE (Molecular Probes) and washed
twice with PBS containing 1% BSA as previously described
(Schnitger et al., 2007). Conﬂuent monolayers of HEp-2 cells
or HUVE cells in 24-well plates were incubated for 4 h at
37°C with 200 mgm l
-1 recombinant protein or 500 mgm l
-1
heparin, and then CFSE-labelled C. pneumoniae EBs were
added (moi 10) for 1 h. Cells were washed with PBS,
trypsinized and ﬁxed with formaldehyde, and adhesion was
measured by ﬂow cytometry using a FACSAria (BD
Biosciences).
Statistical and bioinformatical analysis
CLUSTAL w and GOR IV secondary structure prediction tools
were used for sequence alignments and secondary structure
prediction (http://www.expasy.org/). Statistical analysis of
adhesion assays with latex beads, the infection inhibition
assay and bacterial adhesion assay was carried out by
two-way ANOVA. Statistics for yeast adhesion assays were
subjected to a two-sided Wilcox–Mann–Whitney U-test
and signiﬁcance was assessed by the Bonferroni method
(Krauth, 1988).
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